Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Targets & Mechanisms

Long COVID’s big tent needs to get more precise

Breaking the disease into subtypes will be important for getting more companies into the space

May 8, 2021 2:18 AM UTC

The emerging consensus is that Long COVID should be addressed as a collection of distinct syndromes, even as advocates speak with one voice. Carving the disease into specific pathologies and biomarker-defined subsets will be important for bringing more drug developers into a disease space dominated by the public sector, patient groups and academia.

In the coming weeks, the Long COVID field will receive its first bolus of funding from NIH’s post-acute sequelae of SARS-CoV-2 infection (PASC) Initiative, supported by $1.15 billion in Congressional funding over four years. At an April 28 U.S. Congressional subcommittee hearing on Long COVID, NIH Director Francis Collins said the institute is evaluating 273 grant proposals, and will stand up core facilities and a large metacohort of patients for observational and interventional studies...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article